BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp grew its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 9.6% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 92,228 shares of the medical equipment provider’s stock after purchasing an additional 8,061 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp’s holdings in Hologic were worth $3,791,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds also recently modified their holdings of the company. Lindbrook Capital LLC bought a new stake in Hologic during the 4th quarter worth approximately $36,000. Essex Savings Bank bought a new position in shares of Hologic in the fourth quarter valued at approximately $37,000. Cerebellum GP LLC bought a new position in shares of Hologic in the fourth quarter valued at approximately $43,000. Clean Yield Group bought a new position in shares of Hologic in the fourth quarter valued at approximately $47,000. Finally, Dubuque Bank & Trust Co. bought a new position in shares of Hologic in the fourth quarter valued at approximately $54,000. 88.77% of the stock is owned by hedge funds and other institutional investors.
In other Hologic news, insider Benjamin Jordan Cohn sold 6,830 shares of the stock in a transaction on Monday, March 11th. The stock was sold at an average price of $46.70, for a total transaction of $318,961.00. Following the completion of the transaction, the insider now directly owns 22,002 shares of the company’s stock, valued at $1,027,493.40. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Peter J. Valenti III sold 4,242 shares of the stock in a transaction on Friday, March 1st. The shares were sold at an average price of $47.38, for a total value of $200,985.96. The disclosure for this sale can be found here. 0.90% of the stock is currently owned by corporate insiders.
Shares of NASDAQ HOLX opened at $47.36 on Friday. Hologic, Inc. has a 1-year low of $35.10 and a 1-year high of $48.11. The firm has a market cap of $13.74 billion, a price-to-earnings ratio of 21.24, a PEG ratio of 2.21 and a beta of 0.75. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.30 and a quick ratio of 0.91.
Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, January 30th. The medical equipment provider reported $0.58 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.01. Hologic had a positive return on equity of 25.59% and a negative net margin of 12.88%. The business had revenue of $830.70 million during the quarter, compared to analyst estimates of $823.22 million. During the same period in the prior year, the company earned $0.55 earnings per share. Hologic’s revenue was up 5.0% compared to the same quarter last year. Analysts anticipate that Hologic, Inc. will post 2.41 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This story was posted by Week Herald and is owned by of Week Herald. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://weekherald.com/2019/03/15/british-columbia-investment-management-corp-buys-8061-shares-of-hologic-inc-holx.html.
Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Recommended Story: Cost of Capital Explained
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.